Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.57 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406753 | 0.89 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4406748 | 0.86 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21434731 | 0.84 | CYP1A2 (0.53) | PDK2CYP1A2CYP2C9ALDH1A1KDM4E | |
| SCHEMBL22749456 | 0.84 | CFTR (0.62) | CYP1A2CYP2C9ALDH1A1KDM4EGAA | |
| SCHEMBL4408334 | 0.83 | KDM4E (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1098123 | 0.82 | CYP2C9 (0.73) | CYP1A2CYP2C9ALDH1A1KDM4EMAPT | |
| SCHEMBL24436789 | 0.81 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3207510 | 0.81 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30660469 | 0.81 | KDM4E (0.57) | CYP1A2CYP2C9ALDH1A1KDM4EMAPT | |
| SCHEMBL28255789 | 0.81 | CYP1A2 (0.60) | CYP1A2CYP2C9ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589125-B2 | 2-acetoxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid; methyl 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoate; psoriasis and other immune diseases | PALAU PHARMA, S.A. (ES) | 2009-09-15 | — | — | US | claimed |
| US-20050267205-A1 | 2,4-dihydroxybenzoic acid derivatives | J. URIACH Y COMPANIA S.A. (ES) | 2005-12-01 | — | — | US | claimed |
| EP-1546084-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach y Compania S.A. (ES) | 2005-06-29 | — | — | EP | claimed |
| WO-2004009528-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach Y Compañia S.A. (ES) | 2004-01-29 | — | — | WO | claimed |
| US-7589125-B2 | 2-acetoxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid; methyl 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoate; psoriasis and other immune diseases | PALAU PHARMA, S.A. (ES) | 2009-09-15 | — | — | US | disclosed |
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| US-20050267205-A1 | 2,4-dihydroxybenzoic acid derivatives | J. URIACH Y COMPANIA S.A. (ES) | 2005-12-01 | — | — | US | disclosed |
| EP-1546084-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach y Compania S.A. (ES) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004009528-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach Y Compañia S.A. (ES) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027185-A1 | Antithrombotic aromatic ethers | F2, F11, TFPI | CA12 2570/4885CA1 2130/4885CA2 2701/4885 |
| US-20050267205-A1 | 2,4-dihydroxybenzoic acid derivatives | CYP24A1, NFKBIA, PAH | CA12 1530/4885CA1 1723/4885CA2 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.